Nanjing Sanzhong Pharmaceutical Technology

Nanjing Sanzhong Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Nanjing, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing significant unmet medical needs in the fields of oncology and metabolic diseases. Utilizing its proprietary structure-based drug design platform, Sanzhong has successfully advanced multiple candidates into clinical development, including a selective FGFR4 inhibitor for liver cancer and a URAT1 inhibitor for gout. The leadership team comprises industry veterans with extensive experience in global drug R&D and commercialization. Sanzhong aims to provide high-quality and affordable innovative medicines to patients worldwide through efficient internal research and strategic external collaborations.